These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409 [TBL] [Abstract][Full Text] [Related]
5. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. Cao X; Liang L; Hadcock JR; Iredale PA; Griffith DA; Menniti FS; Factor S; Greenamyre JT; Papa SM J Pharmacol Exp Ther; 2007 Oct; 323(1):318-26. PubMed ID: 17630359 [TBL] [Abstract][Full Text] [Related]
6. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824 [TBL] [Abstract][Full Text] [Related]
7. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients. Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656 [TBL] [Abstract][Full Text] [Related]
8. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698 [TBL] [Abstract][Full Text] [Related]
9. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958. Andringa G; Lubbers L; Drukarch B; Stoof JC; Cools AR Behav Pharmacol; 1999 Mar; 10(2):175-82. PubMed ID: 10780830 [TBL] [Abstract][Full Text] [Related]
10. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135 [TBL] [Abstract][Full Text] [Related]
11. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy. Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606 [TBL] [Abstract][Full Text] [Related]
12. [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys]. Chen S Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):50-2, 64. PubMed ID: 1591961 [TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Schneider JS Pharmacol Biochem Behav; 1989 Sep; 34(1):193-6. PubMed ID: 2576311 [TBL] [Abstract][Full Text] [Related]
14. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. Riahi G; Morissette M; Parent M; Di Paolo T Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255 [TBL] [Abstract][Full Text] [Related]
15. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125 [TBL] [Abstract][Full Text] [Related]
16. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992 [TBL] [Abstract][Full Text] [Related]
17. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys. Bourque M; Grégoire L; Di Paolo T Behav Brain Res; 2018 Jan; 337():183-185. PubMed ID: 28917506 [TBL] [Abstract][Full Text] [Related]
18. A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys. Beck G; Maehara S; Chang PL; Papa SM Mov Disord; 2018 May; 33(5):805-814. PubMed ID: 29508924 [TBL] [Abstract][Full Text] [Related]
19. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910 [TBL] [Abstract][Full Text] [Related]
20. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Papa SM; Chase TN Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]